ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to support once-monthly subcutaneous (SC) administration of a GLP-1 receptor agonist (GLP-1RA) called PLX039 for the treatment of Type 2 diabetes (T2D). The work will be published in ACS Chemical Biology.
GLP-1RAs have emerged as an important standard-of-care drug class for the treatment of Type 2 diabetes and are projected to command a $12 Bill market by 2024. These agonists auto-regulate blood glucose concentration, have anti-obesity effects, and may reduce risks for adverse cardiovascular events in patients with T2D. Currently, there are three once- or twice- daily and three once-weekly GLP-1RAs approved by the FDA; an additional once-weekly agonist and a long-acting osmotic pump delivery system are in late stage trials. Yet, poor medication adherence and persistence remain as major factors leading to failure of glycemic control in almost 50% of T2D patients. Now, ProLynx has used its half-life extension platform to develop a monthly-administered GLP-1RA. Compared to weekly-administered agonists, obvious benefits are believed to include greater patient convenience, compliance and persistence.
Daniel Santi, co-founder and President of ProLynx, said: "This is the first GLP-1RA that does not require huge doses of a drug meant for weekly administration to maintain therapeutic levels over a monthly period." Santi added: "PLX039 should find a dose-interval sweet-spot with its once-monthly administration. Some patients will find that a once-weekly dosing interval is too short, and will not want to have a long-acting osmotic pump implanted; for these patients, the once monthly GLP-1 receptor agonist PLX039 should be just right."
In the ProLynx half-life extension platform, a drug is tethered to hydrogel microspheres by a self-cleaving linker that is pre-programmed to release the drug at a pre-determined rate. After SC injection, the drug is slowly released from the microsphere depot into the systemic circulation. ProLynx attached their peptidic GLP-1RA - a stabilized analog of exenatide - to its hydrogel microspheres. After SC injection to rodents the GLP-1RA showed a serum half-life of one month. Monthly injections of the formulation in diabetic rats showed identical glucoregulatory effects as continuously infused exenatide, and simulation of the pharmacokinetics indicate it should serve well as a once-a-month treatment for T2D in humans.
About ProLynx. ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company may be found at www.ProLynxllc.com.
Contact: Eric Schneider: Eric@ProLynxllc.com Or BD@ProLynxllc.com 415-552-5306
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProLynx LLC via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
CP Kelco Appoints Didier Viala as New President16.10.2017 15:00 | Pressmeddelande
ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat
LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin16.10.2017 15:00 | Pressmeddelande
· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin. Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without th
Invitation to presentation of LeoVegas third quarter 201716.10.2017 14:35 | Pressmeddelande
LeoVegas interim report for the third quarter 2017 will be published at 08:00 CET on October 25, 2017. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and President, and Viktor Fritzén, CFO, will present the results for the third quarter 2017. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/4pk3b55e To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5352 6408 UK: +44 (0) 20 3427 1914 US: + 1646 254 3364 Confirmation code: 35 35 667 The webcast, which afterwards also will be
Inbjudan till presentation av LeoVegas kvartalsrapport för tredje kvartalet 201716.10.2017 14:35 | Pressmeddelande
LeoVegas kvartalsrapport för det tredje kvartalet 2017 kommer att publiceras klockan 08:00 den 25 oktober 2017. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och koncernchef samt Viktor Fritzén, CFO, presenterar resultatet för det tredje kvartalet 2017. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/4pk3b55e För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5352 6408 UK: +44 (0) 20 3427 1914 US: + 1646 254 3364 Bekräftelsekod: 35 35 667 Webbsändningen, som även kan ses i efterhand, och pres
Concurrent Enters Definitive Agreement to Sell Content Delivery & Storage Business to Vecima Networks for $29 Million16.10.2017 14:00 | Pressmeddelande
Proposed Transaction Expected to Result in Debt Free Balance Sheet with $67 Million in Pro Forma Working Capital ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Concurrent Computer Corporation (NASDAQ:CCUR) has entered into a definitive agreement to sell all of the assets of its Content Delivery & Storage Business to Vecima Networks Inc. (TSX:VCM) for a base purchase price of $29 million, subject to adjustment for normalized net working capital. Headquartered in Victoria, British Columbia, Vecima is a leading designer and manufacturer of innovative network technology solutions. The proposed transaction, which has been approved by the Board of Directors of both companies, is subject to various terms and conditions including stockholder approval from Concurrent. "Vecima believes that the rapid growth in IPTV delivery across both MVPD private CDNs and OTT providers will continue to accelerate. Concurrent is a recognized leader in storing, protec
Telefonica Deploys ASSIA's GPON Expresse® Solution to optimize Fiber Broadband Performance16.10.2017 14:00 | Pressmeddelande
REDWOOD CITY, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Adaptive Spectrum and Signal Alignment, Inc. (ASSIA®). ASSIA and Telefonica announce widespread deployment of ASSIA's GPON Expresse® software across countries in South America: Argentina, Brazil, Chile, Colombia and Peru. GPON Expresse manages gigabit optical broadband networks with diagnostics for improved network performance and service delivery to Telefonica's fiber-based subscribers. GPON Expresse adds to the suite of ASSIA software products currently deployed at Telefonica in Latin America: DSL Expresse® for diagnostics and optimization of high speed DSL networks, and ClearView® for precise network analysis and recommendations for customer care agents and field technicians. With the GPON Expresse deployment, Telefonica can now benefit from ClearView support across both copper and fiber networks. By also incorporating ClearView support for Wi-Fi, operators can have complete end-to-end management across their ac
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum